Hyperscale Data Buys $1,000 Series D Preferred in Alzamend Neuro, Betting Big on a Potential Upswing Amid Nasdaq Compliance Scrutiny.
Hyperscale Data’s $1,000 Series D buy of Alzamend Neuro shows bullish insider confidence, offering a cost‑efficient path to equity amid a high‑beta biotech’s upside potential.
4 minutes to read
